Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLGN
stocks logo

CLGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.08M
+1177.23%
-0.070
-79.41%
1.10M
-46.7%
-0.190
+46.15%
9.82M
+5414.99%
0.350
-225%
Estimates Revision
The market is revising Upward the revenue expectations for CollPlant Biotechnologies Ltd. (CLGN) for FY2025, with the revenue forecasts being adjusted by 0.78% over the past three months. During the same period, the stock price has changed by -22.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.78%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-22.79%
In Past 3 Month
Wall Street analysts forecast CLGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CLGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.100
sliders
Low
11.00
Averages
11.00
High
11.00
Current: 2.100
sliders
Low
11.00
Averages
11.00
High
11.00
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$14
2025-03-27
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14
2025-03-27
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$14
2025-02-12
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14
2025-02-12
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$14
2025-02-04
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14
2025-02-04
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Collplant Biotechnologies Ltd (CLGN.O) is -19.09, compared to its 5-year average forward P/E of 9.81. For a more detailed relative valuation and DCF analysis to assess Collplant Biotechnologies Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
9.81
Current PE
-19.09
Overvalued PE
44.29
Undervalued PE
-24.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
55.63
Current PS
0.00
Overvalued PS
168.76
Undervalued PS
-57.49
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CLGN News & Events

Events Timeline

(ET)
2025-11-26
07:35:33
CollPlant to Cut Workforce by 25%
select
2025-11-26
07:32:38
CollPlant announces Q3 non-GAAP EPS of 25 cents, compared to a loss of 33 cents in the previous year.
select
2025-10-27 (ET)
2025-10-27
07:11:14
CollPlant enhances rhCollagen offerings in the U.S. and Canada
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-29NASDAQ.COM
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)

  • Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.

  • Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.

  • Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.

  • Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.

[object Object]
Preview
4.0
11-28Benzinga
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

[object Object]
Preview
7.5
11-26Newsfilter
CollPlant Partners with U.S. Logistics Center to Expand North American Market
  • Market Expansion: CollPlant has established a partnership with a U.S.-based logistics center expected to become operational this quarter, aimed at enhancing distribution capabilities for its rhCollagen and BioInk products across the U.S. and Canada, thereby supporting its growing customer base.
  • Innovation Breakthrough: CollPlant's rhCollagen has been utilized in research at Mayo Clinic to develop the first fully humanized 3D bioprinted skin model, providing a sustainable alternative to animal testing, showcasing its broad application potential in medical and aesthetic fields.
  • Financial Improvement: CollPlant reported GAAP revenues of $77,000 for the third quarter, a significant increase from $4,000 in the same period last year, primarily driven by increased sales of rhCollagen products, indicating a gradual recovery in the market.
  • Cost Control: CollPlant has implemented a cost reduction plan expected to reduce its workforce by approximately 25%, aimed at optimizing resource allocation and extending its cash runway to support future R&D and market expansion.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Collplant Biotechnologies Ltd (CLGN) stock price today?

The current price of CLGN is 2.1 USD — it has increased 1.6 % in the last trading day.

arrow icon

What is Collplant Biotechnologies Ltd (CLGN)'s business?

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

arrow icon

What is the price predicton of CLGN Stock?

Wall Street analysts forecast CLGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Collplant Biotechnologies Ltd (CLGN)'s revenue for the last quarter?

Collplant Biotechnologies Ltd revenue for the last quarter amounts to 77.00K USD, increased 1825.00 % YoY.

arrow icon

What is Collplant Biotechnologies Ltd (CLGN)'s earnings per share (EPS) for the last quarter?

Collplant Biotechnologies Ltd. EPS for the last quarter amounts to -0.27 USD, decreased -28.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for Collplant Biotechnologies Ltd (CLGN)'s fundamentals?

The market is revising Upward the revenue expectations for CollPlant Biotechnologies Ltd. (CLGN) for FY2025, with the revenue forecasts being adjusted by 0.78% over the past three months. During the same period, the stock price has changed by -22.79%.
arrow icon

How many employees does Collplant Biotechnologies Ltd (CLGN). have?

Collplant Biotechnologies Ltd (CLGN) has 57 emplpoyees as of December 05 2025.

arrow icon

What is Collplant Biotechnologies Ltd (CLGN) market cap?

Today CLGN has the market capitalization of 26.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free